Preventing Infections After Hysterectomy: Azithromycin vs. Cefuroxime

We are studying whether a combination of azithromycin and cefuroxime can better prevent infections after hysterectomy compared to cefuroxime alone. This research aims to improve antibiotic use in surgical settings.

>2 yearsMonitoring phase (IV)Investigational MedicinesOralGynecology and ObstetricsInfectious Diseases

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Azithromycin
Azithromycin is an antibiotic substance used to treat common bacterial infections, especially respiratory, ear, skin, and some sexually transmitted infections.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Placebo

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
HUS-Yhtymae
Naistenklinikka
Helsinki, Finland
Kuopio University Hospital
Naistentaudit
Kuopio, Finland
Oulu University Hospital
Naistentaudit
Oulu, Finland
Sponsor: HUS-Yhtymae
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.